Sugi Predict

Sugi Predict / Compounds / SCHEMBL2029059

SCHEMBL2029059

SCHEMBL2029059

CC(=O)On1ncc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 1/20 0.44
▸ ELANE P08246 1/20 0.42
▸ POLB P06746 4/20 0.40
▸ TSHR P16473 3/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ ASAH1 Q13510 2/20 0.40
▸ NOTUM Q6P988 1/20 0.40
▸ SLC22A12 Q96S37 1/20 0.39
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ RECQL P46063 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TFPI2 P48307 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ CYP11B1 P15538 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1162916 0.86 KMO (0.46) KMOELANEPOLBTSHRHSD17B10
SCHEMBL536315 0.83 KMO (0.45) KMOELANEPOLBTSHRHSD17B10
SCHEMBL1854888 0.83 KMO (0.44) KMOELANEPOLBTSHRHSD17B10
SCHEMBL19543121 0.82 KMO (0.41) KMOELANEPOLBTSHRHSD17B10
SCHEMBL27664784 0.82 KMO (0.41) KMOELANEPOLBTSHRHSD17B10
SCHEMBL3410551 0.81 KMO (0.43) KMOELANEPOLBTSHRHSD17B10
SCHEMBL5215616 0.81 KMO (0.43) KMOELANEPOLBTSHRHSD17B10
SCHEMBL27642117 0.81 KMO (0.47) KMOELANEPOLBTSHRHSD17B10
SCHEMBL19543143 0.80 KMO (0.39) KMOELANEPOLBTSHRHSD17B10
SCHEMBL3923482 0.80 KMO (0.39) KMOELANEPOLBTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101632357-A Composition for culturing seedlings, enhancing roots and strengthening seedlings in cotton nutritionpot and preparation method thereof BINGJUN WANG 2010-01-27 — — CN claimed
CN-1214690-A Specific immunophilin ligands as antiasthmatics and immunosuppressants ASTA MEDICA AG (DE) 1999-04-21 — — CN claimed
US-9725442-B2 Heterocyclic derivative having PGD2 receptor antagonist activity SHIONOGI & CO., LTD. (JP) 2017-08-08 — — US disclosed
EP-2752410-B1 HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY SHIONOGI & CO (JP) 2016-08-31 — — EP disclosed
US-20140275074-A1 HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY SHIONOGI & CO., LTD. (JP) 2014-09-18 — — US disclosed
EP-2752410-A1 HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY Shionogi & Co., Ltd. (JP) 2014-07-09 — — EP disclosed
CN-102260214-B Method for preparing indazole compound UNIV ZHEJIANG 2013-12-04 — — CN disclosed
CN-102260214-B Method for preparing indazole compound UNIV ZHEJIANG 2013-12-04 — — CN disclosed
US-8293923-B2 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase BIOGEN IDEC MA INC. (US) 2012-10-23 — — US disclosed
CN-102617464-A fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor ABBOTT LAB 2012-08-01 — — CN disclosed
CN-101747277-B Application and preparation of indazole compound UNIV ZHEJIANG 2012-01-25 — — CN disclosed
EP-2061786-A2 INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE Biogen Idec MA Inc. (US) 2009-05-27 — — EP disclosed
CN-101443327-A Chromanylurea compounds that inhibit vanilloid receptor subtype 1(VR1) receptor and uses thereof ABBOTT LAB (US) 2009-05-27 — — CN disclosed
WO-2008030584-A2 INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN- 1 RECEPTOR-ASSOCIATED KINASE BIOGEN IDEC MA INC. (US) 2008-03-13 — — WO disclosed
US-20080027092-A1 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders ASTRAZENECA AB (SE) 2008-01-31 — — US disclosed
CN-1906189-A 1-acetic acid-indole, -indazole and-benzimidazole derivatives for the treatment of respiratory diseases ASTRAZENECA AB (SE) 2007-01-31 — — CN disclosed
CN-1835924-A Fused compounds that inhibit vanilloid receptor subtype 1(vr1) receptor ABBOTT LAB (US) 2006-09-20 — — CN disclosed
EP-1699781-A1 1-ACETIC ACID-INDOLE, -INDAZOLE AND -BENZIMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RESPIRATORY DISORDERS AstraZeneca AB (SE) 2006-09-13 — — EP disclosed
WO-2005054232-A1 1-ACETIC ACID-INDOLE, -INDAZOLE AND-BENZIMIDAZOLE DERIVATIVES USFUL FOR THE TREATMENT OF RESPIRATORY DISORDERS ASTRAZENECA AB (SE) 2005-06-16 — — WO disclosed
CN-1214690-A Specific immunophilin ligands as antiasthmatics and immunosuppressants ASTA MEDICA AG (DE) 1999-04-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275074-A1 HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY PTGDR, PTGDR2, PTGER4 KMO 2510/4885ELANE 3736/4885POLB 3402/4885
US-20080027092-A1 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders IDO1, ABAT, ECI1 KMO 128/4885ELANE 664/4885POLB 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.